Skip to content

Randomized control trial comparing efficacy of brand versus generic diacerein (DIACERIC) for osteoarthritis knee treatment

Randomized control trial comparing efficacy of brand versus generic diacerein (DIACERIC) for osteoarthritis knee treatment

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240514004
Enrollment
94
Registered
2024-05-14
Start date
2023-02-07
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis Osteoarthritis knee, Diacerein, Visual analog scale (VAS), Patient-reported outcome measures (PROMs), Performance-based measures (PBMs).

Interventions

To receive 50 mg generic diacerein (Diaceric) orally, twice daily for 6 months.,To receive 50 mg brand diacerein (Artrodar) orally, twice daily for 6 months.
Experimental Drug,Active Comparator Drug
generic diacerein (Diaceric),brand diacerein (Artrodar)

Sponsors

Millimed.Co.Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. 50 years of age or more 2. Knee OA according to the criteria of the American College of Rheumatology 3. Radiographic grade I-III by the Kellgren/Lawrence classification 4. Pain score of more than 30 mm on a 100-mm visual analog scale (VAS)

Exclusion criteria

Exclusion criteria: 1. Secondary OA 2. Previous surgery on the same knee or knee surgery planned within the following 6months. 3. Lower limb surgery within the last 6 months. 4. Radiographic grade IV by the Kellgren/Lawrence classification 5. Have been treated with any symptomatic slow-acting drugs for osteoarthritis (SYSADOA) within 6 months prior to study. 6. Have been treated with any intraarticular injection (corticosteroids, hyaluronic acid) for at least 3 months before the study. 7. Severe gastrointestinal disorders. 8. Persistent diarrhea (> 3 stools/24 hours) or laxative use. 9. Serious concomitant medical illness or major co-morbidity precluding aerobic exercise at 50-60%maximum heart rate.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale (VAS) at 6 months after the beginning of intervention Visual Analog Scale (VAS)

Secondary

MeasureTime frame
patient-reported outcome measures (PROMs) at 6 months after the beginning of intervention Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index,patient-reported outcome measures (PROMs) at 6 months after the beginning of intervention Short Form-12 (SF-12),performance-based measures (PBMs) at 6 months after the beginning of intervention time up and go (TUG),performance-based measures (PBMs) at 6 months after the beginning of intervention 5-time sit to stand test (5 x SST),performance-based measures (PBMs) at 6 months after the beginning of intervention 3-min walk test (3-min WT)

Countries

Thailand

Contacts

Public ContactAree Tanavalee

Faculty of Medicine, Chulalongkorn University

areetana@hotmail.com022564510

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026